Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary
- 21 July 2006
- journal article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (11), 1469-1474
- https://doi.org/10.1517/14656566.7.11.1469
Abstract
Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the breast and ovary. Furthermore, Phase II and III trial experience has revealed that the drug produces objective responses comparable in rate and duration to doxorubicin and other single agents employed in metastatic breast cancer. In recurrent and platinum-resistant ovarian cancer, single-agent pegylated liposomal doxorubicin has assumed an important role in routine patient management.Keywords
This publication has 33 references indexed in Scilit:
- Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancersGynecologic Oncology, 2005
- Cardiac safety profile of prolonged (≥6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignanciesGynecologic Oncology, 2004
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 2003
- Anthracyclines in the Treatment of Gynecologic MalignanciesGynecologic Oncology, 2002
- The Costs and Efficacy of Liposomal Doxorubicin in Platinum-Refractory Ovarian Cancer in Heavily Pretreated PatientsGynecologic Oncology, 2001
- Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent DosagesGynecologic Oncology, 2001
- The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian CancerGynecologic Oncology, 2001
- Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicinCancer, 2001
- Polyethylene Glycol-Liposomal DoxorubicinDrugs, 1997